ABUS Arbutus Biopharma Corporation - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 12, 2026
$4.45
· of 52w range
· above low
· to high
$3.6752w low
$5.4552w high
Market Cap (MRQ)
$879M
P/E (TTM)
5.6
EPS (TTM)
$0.79
Revenue (TTM)
$182M
your badges
52W Range
$4–$5
Analyst Rating
STRONG BUY
Price Target
$5
P/E
5.6
ROE
89.6%
Net Profit Margin
84.2%
Your badge strip is empty — pin a metric anywhere on this page.
ABUS Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$4.45
Market Cap (MRQ)
$879M
P/E (TTM)
5.6
EPS (TTM)
$0.79
Revenue (TTM)
$182M
ROE (TTM)
89.6%
52W Range
$4–$5
ABUS Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| Nov. 4, 2010 | 1-for-5 | Reverse |
About Arbutus Biopharma Corporation - Common Stock Company overview from Wikipedia
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.
History
Tekmira, as the company was formerly called, was formed as a wholly owned subsidiary of Inex Pharmaceuticals in 2005 after that company began collapsing after its regulatory and partnering strategy failed in 2004. Tekmira was fully spun out in 2007 and Tekmira absorbed the assets of Inex, which had been founded in 1992.
Inex had been developing liposomal formulations of off-patent cancer drugs, and licensed them to Talon Pharmaceuticals in 2005; Talon was acquired by Spectrum Pharmaceuticals in 2013, and three former Inex/Tekmira products reached the market and began generating royalties for Tekmira: Marqibo (liposomal vincristine), Alocrest (liposomal vinorelbine) and Brakiva (liposomal topotecan).
Inex had also acquired licenses to intellectual property, as well as staff and manufacturing facilities, concerning RNAi technology from Lynx Therapeutics in 1998; this set of technologies became the focus for Tekmira and it initially sought to develop liposomally encapsulated RNAi drugs for a broad range of indications.
Tekmira also worked on providing liposomal delivery technology to other companies. In 2007 it signed a license agreement with Alnylam Pharmaceuticals so that Alnylam could use it to deliver its own RNAi drugs; that deal was expanded into a manufacturing agreement in 2009.
Most of those products not focused on viral diseases faltered, and Tekmira had only $6.3 million in cash when it filed suit against Alnylam in 2011 for breaching its contract and stealing trade secrets. The suit was settled in 2012, with Alnylam agreeing to pay Tekmira $65 million in termination fees, and the companies negotiated a new license agreement with lower milestones and royalties, which covers Alnylam's product patisiran.
Tekmira caught the world's attention and its stock rose dramatically during the 2013 West African Ebola virus epidemic due to its drug candidate for Ebola fever, TKM-Ebola. Tekmira was developing it under a $140 million US Department of Defense contract. While its stock was trading high in January 2015, it acquired OnCore BioPharma, a company focused on hepatitis B.
On December 19, 2014, Tekmira announced the appointment of former Bill & Melinda Gates Foundation CFO Richard Henriques to the company's board of directors. The company simultaneously announced the forthcoming departure of Ian MacLachlan as Executive Vice President and Chief Technical Officer.
Development of TKM-Ebola was terminated in mid June 2015 during a Phase II trial, for lack of efficacy.
The next month, Tekmira changed its name to Arbutus Biopharma and said that it would focus on drugs to treat hepatitis B.
In March 2017 Arbutus signed another license for its liposome delivery technology, this time with Alexion Pharmaceuticals, for delivery of an mRNA drug candidate. This license was terminated in July 2017, when Alexion discontinued preclinical programs outside its core complement franchise.
In 2019, Arbutus began a phase 1 clinical study using AB-506 to treat chronic hepatitis B. The company released preliminary data in July and stopped the trial in October after two patients developed acute hepatitis. Now AB-729 is paving the way for Arbutus, as they recently received the FDA go ahead to pursue phase 2 trials, after having their data voted best in ILC, 2021; after abandoning development of previous investigational agents. AB-836, Arbutus's next generation capsid inhibitor, has shown potential against mutants in its phase 1 trials.
In July 2019, Arbutus Biopharma announced the sale of part of its royalty interest on future global net sales of ONPATTRO, an RNA interference therapeutic currently sold by Alnylam Pharmaceuticals, to OMERS for $20 million.
COVID-19
On March 10, 2023, U.S. District Judge Mitchell Goldberg rejected a bid by Moderna to dismiss some of the patent infringement claims brought against the company by Arbutus and its partner, Genevant Sciences.
Moderna settled their lawsuit and will pay Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealthcare
industryBiotechnology
employees19
countryCA
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$14M2016-12-31 → 2025-12-31
EPS$-0.172016-12-31 → 2025-12-31
Free Cash Flow$-40M2016-12-31 → 2025-12-31
Net margin84.2%2016-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | ABUS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | 5.65Y avg ≈-10.5 | ≈-10.5 | · | · | |
| P/S (TTM) | 4.85Y avg ≈50.1 | ≈50.1 | 10.3 | Undervalued | |
| P/B (MRQ) | 3.45Y avg ≈5.7 | ≈5.7 | 3.7 | Fair value | |
| Price / FCF | -22.15Y avg ≈-11.3 | ≈-11.3 | · | · | |
| Price / Cash Flow | -22.15Y avg ≈-11.3 | ≈-11.3 | · | · | |
| Price / Tangible Book | 11.45Y avg ≈5.7 | ≈5.7 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | ABUS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | 82.0%5Y avg ≈-555.0% | ≈-555.0% | -588.2% | In line | |
| EBITDA Margin | -271.0%5Y avg ≈-555.0% | ≈-555.0% | -588.2% | In line | |
| Net Profit Margin (TTM) | 84.2%5Y avg ≈-528.9% | ≈-528.9% | -507.2% | In line | |
| ROA (TTM) | 81.1%5Y avg ≈-40.5% | ≈-40.5% | -29.6% | In line | |
| ROE (TTM) | 89.6%5Y avg ≈-55.0% | ≈-55.0% | -42.0% | In line |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | ABUS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 81.45Y avg ≈9.7 | ≈9.7 | 9.6 | Strong liquidity | |
| Quick Ratio | 15.55Y avg ≈9.5 | ≈9.5 | 6.6 | In line |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | ABUS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 128.2%5Y avg ≈64.5% | ≈64.5% | · | · | |
| Revenue CAGR 3Y | -28.8%5Y avg ≈-2.8% | ≈-2.8% | · | · | |
| Revenue CAGR 5Y | 15.3% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | ABUS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.15Y avg ≈0.1 | ≈0.1 | 0.2 | Weak | |
| Receivables Turnover | 7.35Y avg ≈13.3 | ≈13.3 | · | · | |
| Revenue / Employee | ≈$741.2K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
581.5%
Next Report
Nov 11, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 4, 2026 | $-0.03 | $-0.02 | -47.1% |
| March 31, 2026 | May 12, 2026 | $1.19 | $-0.03 | 3988.9% |
| Dec. 31, 2025 | $-0.02 | $-0.04 | 44.0% | |
| Sept. 30, 2025 | $-0.04 | $-0.03 | -26.6% | |
| June 30, 2025 | $0.01 | $-0.05 | 120.6% | |
| March 31, 2025 | $-0.13 | $-0.11 | -23.2% | |
| Dec. 31, 2024 | $-0.07 | $-0.08 | 14.2% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| R&D Expense | $25M | $54M | $74M | $84M | $66M | $49M | $58M | $58M | $63M | $61M | $52M | |
| SG&A Expense | $16M | $22M | $22M | $18M | $17M | $15M | $18M | $16M | $16M | $39M | $26M | |
| Operating Expenses | $52M | $82M | $96M | $104M | $85M | $65M | $150M | $96M | $122M | $493M | $127M | |
| Operating Income | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | $-144M | $-90M | $-111M | $-492M | $-104M | |
| Interest Expense | · | · | $459.0K | $2M | $3M | $4M | $2M | $226.0K | $261.0K | $0 | $0 | |
| Interest Income | $4M | $7M | $6M | $2M | $127.0K | $741.0K | $2M | $3M | $2M | $1M | $674.0K | |
| Other Non-op | $5M | $6M | $5M | $444.0K | $-3M | $-6M | $-22M | $28M | $2M | $2M | $25M | |
| Pretax Income | · | · | · | · | · | $-64M | $-166M | $-61M | $-109M | $-489M | $-79M | |
| Income Tax | $0 | $0 | $0 | $4M | $0 | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Net Income | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| EPS (Basic) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| EPS (Diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| Shares (Basic) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| Shares (Diluted) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| EBITDA | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | · | $-90M | $-111M | $-492M | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18M | $36M | $26M | $31M | $109M | $52M | $32M | $37M | $54M | $23M | $167M | |
| Short-term Investments | $73M | $86M | $100M | $116M | $46M | $71M | $59M | $88M | $72M | $107M | $15M | |
| Receivables | $1M | $2M | $2M | $1M | $899.0K | $1M | $1M | $1M | $402.0K | $273.0K | $1M | |
| Prepaid Expense | $2M | $2M | $4M | $3M | $4M | $3M | $2M | $3M | $2M | $1M | $1M | |
| Current Assets | $94M | $127M | $132M | $151M | $161M | $128M | $94M | $129M | $129M | $133M | $184M | |
| PP&E (Net) | $32.0K | $3M | $5M | $5M | $6M | $7M | $9M | $10M | $12M | $7M | $3M | |
| PP&E (Gross) | $245.0K | $16M | $17M | $16M | $15M | $15M | $14M | $17M | $25M | $18M | $13M | |
| Accum. Depreciation | $213.0K | $13M | $12M | $11M | $9M | $8M | $6M | $7M | $13M | $11M | $10M | |
| Goodwill | · | · | · | · | · | · | $0 | $22M | $24M | $24M | $163M | |
| Intangibles | · | · | · | · | · | · | $0 | $44M | $59M | $99M | $353M | |
| Other Non-current Assets | $130.0K | $34.0K | $0 | $103.0K | $61.0K | $44.0K | $293.0K | $0 | · | · | · | |
| Total Assets | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Accounts Payable | $5M | $8M | $10M | $16M | $11M | $9M | $7M | $9M | $11M | $10M | $9M | |
| Current Liabilities | $6M | $16M | $22M | $33M | $11M | $10M | $8M | $11M | $15M | $11M | $11M | |
| Capital Leases | $199.0K | $806.0K | $1M | $2M | $2M | $3M | $3M | $0 | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $13M | $17M | $41M | $146M | |
| Total Liabilities | $18M | $34M | $38M | $59M | $35M | $35M | $33M | $28M | $55M | $73M | $165M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Common Stock | $1.42B | $1.41B | $1.35B | $1.32B | $1.29B | $986M | $899M | $879M | $876M | $867M | $834M | |
| Paid-in Capital | $83M | $82M | $81M | $72M | $65M | $61M | $55M | $48M | $43M | $37M | $30M | |
| Retained Earnings | $-1.38B | $-1.35B | $-1.28B | $-1.20B | $-1.13B | $-1.05B | $-970M | $-805M | $-738M | $-653M | $-267M | |
| AOCI | $-48M | $-48M | $-48M | $-50M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-50M | |
| Stockholders' Equity | $77M | $97M | $106M | $137M | $169M | $102M | $73M | $200M | $182M | $203M | $548M | |
| Liabilities + Equity | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Shares Outstanding | 192,531,225 | 189,963,492 | 169,867,414 | 157,455,363 | 144,987,736 | 89,678,722 | 64,780,314 | 55,518,800 | 55,060,650 | 54,841,494 | 54,570,691 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $9M | $9M | $7M | $6M | $6M | $7M | $6M | $15M | · | · | |
| Deferred Tax | · | · | · | · | · | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Restructuring | $13M | $4M | $0 | · | $0 | $64.0K | $156.0K | $5M | $0 | · | · | |
| Operating Cash Flow | $-40M | $-65M | $-86M | $-35M | $-68M | $-51M | $-71M | $-68M | $-49M | $-58M | $-56M | |
| CapEx | $0 | $182.0K | $1M | $512.0K | $809.0K | $229.0K | $589.0K | $1M | $7M | $4M | $2M | |
| Investing Cash Flow | $16M | $23M | $51M | $-75M | $-13M | $-15M | $28M | $-4M | $28M | $-99M | $8M | |
| Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | · | |
| Stock Issued | · | · | · | · | $135M | $86M | $19M | $0 | $0 | $0 | $142M | |
| Net Stock Activity | · | · | · | · | $135M | $86M | · | · | $0 | $0 | · | |
| Financing Cash Flow | $6M | $52M | $31M | $32M | $137M | $87M | $37M | $56M | $49M | $13M | $144M | |
| Net Change in Cash | $-18M | $10M | $-4M | $-79M | $57M | $20M | $-5M | $-17M | $31M | $-143M | $95M | |
| Free Cash Flow | $-40M | $-65M | $-87M | $-36M | $-68M | $-52M | · | $-69M | $-56M | $-62M | · | |
| Levered FCF | · | · | · | · | · | $-56M | · | $-69M | $-56M | · | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| Net Margin | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | · | -959.8% | -788.9% | -25765.5% | · | |
| Pretax Margin | · | · | · | · | · | -922.0% | · | -1031.8% | -1016.2% | -32807.9% | · | |
| EBITDA Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| ROA | -29.6% | -50.6% | -42.9% | -34.7% | -44.6% | -52.5% | · | -24.5% | -32.9% | -77.8% | · | |
| ROE | -42.0% | -68.5% | -64.6% | -49.2% | -50.9% | -64.0% | · | -27.5% | -43.8% | -102.4% | · | |
| ROIC | · | · | · | · | · | -56.7% | · | -41.7% | -47.2% | -190.2% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 | 13.4 | · | 11.5 | 8.8 | 12.5 | · | |
| Quick Ratio | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 | 13.1 | · | 11.2 | 8.7 | 12.4 | · | |
| Interest Coverage | · | · | -170.2 | -37.9 | -25.7 | -14.4 | · | -397.3 | -425.0 | · | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | 7.3 | 2.9 | 11.6 | 34.7 | 9.9 | 5.5 | · | 6.5 | 31.7 | 2.3 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.40 | $0.51 | $0.62 | $0.87 | $1.17 | $1.14 | · | $3.61 | $3.31 | $3.70 | · | |
| Revenue / Share | $0.07 | $0.03 | $0.11 | $0.26 | $0.10 | · | · | $0.11 | $0.20 | $0.03 | · | |
| Cash Flow / Share | $-0.21 | $-0.35 | $-0.52 | $-0.23 | $-0.64 | · | · | $-1.23 | $-0.89 | $-1.09 | · | |
| Cash / Share | $0.09 | $0.19 | $0.15 | $0.20 | $0.75 | $0.58 | · | $0.67 | $0.99 | $0.43 | · | |
| EPS (TTM) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | $-1.32 | $-1.21 | $-1.56 | $-7.24 | $-1.38 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 128.2% | -66.0% | -53.5% | 255.1% | 58.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -28.8% | -17.5% | 37.9% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.3% | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| Net Income TTM | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| Market Cap | $926M | $621M | $425M | $367M | $564M | $318M | · | $213M | $278M | $134M | · | |
| P/E | -28.3 | -8.6 | -5.7 | -5.1 | -4.7 | -3.5 | -2.1 | -3.2 | -3.2 | -0.3 | -3.2 | |
| P/S | 65.8 | 100.7 | 23.4 | 9.4 | 51.3 | 46.0 | · | 35.8 | 26.0 | 90.1 | · | |
| P/B | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | 1.1 | 1.5 | 0.7 | · | |
| P / Tangible Book | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | · | · | · | · | |
| P / Cash Flow | -23.4 | -9.6 | -4.9 | -10.4 | -8.4 | -6.2 | · | -3.1 | -5.7 | -2.3 | · | |
| P / FCF | -23.4 | -9.6 | -4.9 | -10.2 | -8.3 | -6.2 | · | -3.1 | -5.0 | -2.2 | · | |
| Earnings Yield | -3.5% | -11.6% | -17.6% | -19.7% | -21.3% | -28.2% | -47.5% | -31.6% | -30.9% | -295.5% | -31.0% |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $179M | $1M | $529.0K | $11M | $2M | $2M | $1M | $2M | $2M | $2M | $5M | $5M | $7M | $6M | $6M | |
| R&D Expense | $3M | $4M | $5M | $6M | $5M | $9M | $9M | $14M | $16M | $15M | $18M | $20M | $18M | $18M | $23M | $20M | |
| SG&A Expense | $4M | $6M | $4M | $3M | $3M | $6M | $5M | $5M | $8M | $5M | $5M | $6M | $6M | $6M | $4M | $3M | |
| Operating Expenses | $7M | $10M | $6M | $9M | $9M | $27M | $16M | $23M | $23M | $21M | $23M | $26M | $23M | $24M | $29M | $24M | |
| Operating Income | $-6M | $169M | $-5M | $-9M | $1M | $-26M | $-14M | $-21M | $-22M | $-19M | $-21M | $-22M | $-18M | $-17M | $-23M | $-18M | |
| Interest Expense | · | · | · | · | · | · | · | · | $34.0K | $44.0K | · | $46.0K | $171.0K | $198.0K | $309.0K | $429.0K | |
| Interest Income | $842.0K | $815.0K | $877.0K | $952.0K | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $943.0K | $694.0K | |
| Other Non-op | $821.0K | $787.0K | $2M | $917.0K | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $630.0K | $244.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | $-20M | $-17M | $-16M | · | $-18M | |
| Income Tax | $0 | $0 | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-5M | $170M | $-4M | $-8M | $3M | $-25M | $-13M | $-20M | $-20M | $-18M | $-19M | $-20M | $-17M | $-16M | $-22M | $-18M | |
| EPS (Basic) | $-0.03 | $0.88 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| EPS (Diluted) | $-0.03 | $0.87 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| Shares (Basic) | 197,470,724 | 193,768,641 | · | 191,778,950 | 191,551,282 | 190,707,085 | · | 188,997,194 | 188,041,489 | 175,625,552 | · | 167,512,708 | 166,063,284 | 161,643,404 | · | 150,995,191 | |
| Shares (Diluted) | 197,470,724 | 195,214,067 | · | 191,778,950 | 192,399,733 | 190,707,085 | · | 188,997,194 | 188,041,489 | 175,625,552 | · | 167,512,708 | 166,063,284 | 161,643,404 | · | 150,995,191 | |
| EBITDA | $-6M | $169M | · | $-9M | $1M | $-25M | · | $-21M | $-22M | $-19M | · | $-22M | $-18M | $-17M | · | $-18M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $24M | $18M | $22M | $37M | $37M | $36M | $32M | $63M | $43M | $26M | $18M | $27M | $41M | $31M | $24M | |
| Short-term Investments | · | · | $73M | · | · | · | $86M | · | · | · | $100M | · | · | · | $116M | · | |
| Receivables | $369.0K | $1M | $1M | $905.0K | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $1M | $2M | |
| Prepaid Expense | $2M | $2M | $2M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | $4M | $3M | $3M | $5M | |
| Current Assets | $274M | $277M | $94M | $97M | $103M | $117M | $127M | $133M | $148M | $136M | $132M | $142M | $159M | $153M | $151M | $141M | |
| PP&E (Net) | $10.0K | $22.0K | $32.0K | $137.0K | $148.0K | $168.0K | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | |
| PP&E (Gross) | · | · | $245.0K | · | · | · | $16M | · | · | · | $17M | · | · | · | $16M | · | |
| Accum. Depreciation | $235.0K | $224.0K | $213.0K | $13M | $13M | $13M | $13M | $13M | $13M | $12M | $12M | $12M | $11M | $11M | $11M | $10M | |
| Other Non-current Assets | $132.0K | $131.0K | $130.0K | $131.0K | $0 | $34.0K | $34.0K | · | · | · | $0 | $3.0K | $11.0K | $62.0K | $103.0K | $167.0K | |
| Total Assets | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Accounts Payable | $3M | $4M | $5M | $5M | $5M | $12M | $8M | $8M | $11M | $8M | $10M | $10M | $9M | $10M | $16M | $12M | |
| Current Liabilities | $3M | $5M | $6M | $5M | $5M | $19M | $16M | $19M | $23M | $20M | $22M | $22M | $25M | $25M | $33M | $28M | |
| Capital Leases | $0 | $0 | $199.0K | $391.0K | $575.0K | $626.0K | $806.0K | $978.0K | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $15M | $17M | $18M | $20M | $20M | $38M | $34M | $34M | $38M | $36M | $38M | $39M | $42M | $47M | $59M | $58M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Common Stock | $1.45B | $1.44B | $1.42B | $1.42B | $1.42B | $1.42B | $1.41B | $1.41B | $1.40B | $1.38B | $1.35B | $1.35B | $1.34B | $1.34B | $1.32B | $1.31B | |
| Paid-in Capital | $74M | $74M | $83M | $83M | $83M | $82M | $82M | $81M | $82M | $80M | $81M | $80M | $77M | $74M | $72M | $71M | |
| Retained Earnings | $-1.22B | $-1.21B | $-1.38B | $-1.38B | $-1.37B | $-1.37B | $-1.35B | $-1.33B | $-1.31B | $-1.29B | $-1.28B | $-1.26B | $-1.24B | $-1.22B | $-1.20B | $-1.18B | |
| AOCI | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-49M | $-49M | $-50M | $-50M | $-51M | |
| Stockholders' Equity | $259M | $260M | $77M | $77M | $83M | $79M | $97M | $107M | $122M | $115M | $106M | $119M | $135M | $144M | $137M | $146M | |
| Liabilities + Equity | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Shares Outstanding | 197,634,118 | 196,947,757 | 192,531,225 | 191,953,665 | 191,641,511 | 191,481,474 | 189,963,492 | 189,438,135 | 188,739,044 | 180,192,227 | 169,867,414 | 167,695,247 | 166,922,739 | 165,132,193 | 157,455,363 | 152,711,702 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11.0K | $11.0K | · | $11.0K | $11.0K | $330.0K | · | $336.0K | $356.0K | $355.0K | · | $369.0K | $342.0K | $334.0K | · | $343.0K | |
| Stock-based Comp | $2M | $1M | $1M | $1M | $864.0K | $4M | $2M | $2M | $3M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | |
| Restructuring | $0 | $0 | $-12M | $98.0K | $165.0K | $12M | $95.0K | $4M | $0 | $0 | $0 | $0 | · | · | · | · | |
| Other Non-cash | · | $-179M | · | · | · | $7M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-6M | $-8M | $-5M | $-6M | $-16M | $-13M | $-10M | $-21M | $-15M | $-19M | $-17M | $-22M | $-20M | $-27M | $-17M | $-19M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $86.0K | $0 | $1.0K | $95.0K | $0 | $32.0K | $859.0K | $117.0K | $134.0K | $91.0K | |
| Investing Cash Flow | $-2M | $2M | $-1M | $-10M | $16M | $11M | $13M | $-12M | $10M | $12M | $22M | $10M | $1M | $17M | $13M | $-14M | |
| Financing Cash Flow | $3M | $12M | $2M | $844.0K | $453.0K | $3M | $1M | $2M | $24M | $24M | $4M | $2M | $5M | $20M | $11M | $9M | |
| Net Change in Cash | $-5M | $6M | $-4M | $-15M | $336.0K | $746.0K | $4M | $-31M | $20M | $17M | $9M | $-10M | $-13M | $10M | $7M | $-23M | |
| Free Cash Flow | · | · | · | · | · | $-13M | · | · | · | $-19M | · | · | · | $-27M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-28M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1456.9% | · | -1601.2% | -1250.5% | -1263.9% | · | -462.8% | -395.3% | -260.4% | · | -299.2% | |
| Net Margin | -507.2% | 94.7% | · | -1463.5% | 23.5% | -1390.4% | · | -1472.5% | -1146.9% | -1166.8% | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| EBITDA Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1438.2% | · | -1601.2% | -1250.5% | -1240.7% | · | -462.8% | -395.3% | -255.4% | · | -299.2% | |
| ROA | -2.7% | 86.1% | · | -6.5% | 1.9% | -18.4% | · | -13.2% | -11.8% | -10.5% | · | -11.1% | -8.7% | -7.6% | · | -9.5% | |
| ROE | -3.0% | 100.0% | · | -8.4% | 2.5% | -25.3% | · | -17.4% | -15.4% | -13.8% | · | -15.2% | -11.9% | -10.5% | · | -12.8% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -18.1% | -13.7% | -12.1% | · | -12.2% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 81.4 | 54.3 | · | 18.8 | 20.5 | 6.0 | · | 7.0 | 6.6 | 6.7 | · | 6.3 | 6.5 | 6.1 | · | 5.1 | |
| Quick Ratio | 5.8 | 4.9 | · | 4.5 | 7.7 | 2.0 | · | 1.8 | 2.9 | 2.2 | · | 0.9 | 1.2 | 1.7 | · | 0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -634.8 | -440.1 | · | -468.7 | -107.5 | -87.9 | · | -41.5 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.9 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.5 | 143.6 | · | 0.4 | 7.7 | 1.1 | · | 0.7 | 0.8 | 0.6 | · | 2.3 | 2.0 | 3.4 | · | 3.4 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.31 | $1.32 | · | $0.40 | $0.43 | $0.41 | · | $0.56 | $0.65 | $0.64 | · | $0.71 | $0.81 | $0.87 | · | $0.95 | |
| Revenue / Share | $0.01 | $0.92 | · | $0.00 | $0.06 | $0.01 | · | $0.01 | $0.01 | $0.01 | · | $0.03 | $0.03 | $0.04 | · | $0.04 | |
| Cash Flow / Share | · | $-0.04 | · | · | · | $-0.07 | · | · | · | $-0.11 | · | · | · | $-0.17 | · | · | |
| Cash / Share | $0.10 | $0.12 | · | $0.12 | $0.20 | $0.19 | · | $0.17 | $0.33 | $0.24 | · | $0.10 | $0.16 | $0.25 | · | $0.16 | |
| EPS (TTM) | $0.79 | $0.83 | · | $-0.23 | $-0.29 | $-0.41 | · | $-0.43 | $-0.45 | $-0.44 | · | $-0.45 | $-0.45 | $-0.45 | · | $-0.48 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $182M | $191M | · | $15M | $15M | $6M | · | $7M | $10M | $13M | · | $22M | $24M | $33M | · | $36M | |
| Net Income TTM | $153M | $161M | · | $-42M | $-54M | $-77M | · | $-77M | $-77M | $-74M | · | $-75M | $-73M | $-70M | · | $-69M | |
| Market Cap | $949M | $886M | · | $871M | $592M | $668M | · | $729M | $583M | $465M | · | $340M | $384M | $500M | · | $292M | |
| P/E | 6.1 | 5.4 | · | -19.7 | -10.7 | -8.5 | · | -9.0 | -6.9 | -5.9 | · | -4.5 | -5.1 | -6.7 | · | -4.0 | |
| P/S | 5.2 | 4.6 | · | 59.7 | 38.4 | 104.4 | · | 108.2 | 58.0 | 35.8 | · | 15.3 | 16.3 | 15.1 | · | 8.1 | |
| P/B | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Tangible Book | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Cash Flow | · | -109.3 | · | · | · | -49.9 | · | · | · | -24.1 | · | · | · | -18.3 | · | · | |
| Earnings Yield | 16.5% | 18.4% | · | -5.1% | -9.4% | -11.8% | · | -11.2% | -14.6% | -17.1% | · | -22.2% | -19.6% | -14.8% | · | -25.1% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $14M | $6M | $18M | $39M | $11M |
| Operating Margin % | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% |
| Net Income | $-34M | $-70M | $-73M | $-69M | $-76M |
| Diluted EPS | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 |
| Quick Ratio | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $-40M | $-65M | $-87M | $-36M | $-68M |
Institutional owners (13F) 187 filers · $719.6M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
187
Value held
$719.6M
New positions
35
Exited positions
23
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 35 (+3 vs prior Q) | 23 (-8 vs prior Q) | 62 (+13 vs prior Q) | 42 (-10 vs prior Q) | +466K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Two Seas Capital LP | $91,658,798 | 19,095,583 | 12.74% | Shares |
| MORGAN STANLEY | $84,951,868 | 17,698,305 | 11.81% | Shares |
| Whitefort Capital Management, LP | $75,812,453 | 15,794,261 | 10.54% | Shares |
| BlackRock, Inc. | $66,077,140 | 13,766,071 | 9.18% | Shares |
| VANGUARD GROUP INC | $44,456,122 | 9,242,437 | 6.18% | Shares |
| STATE STREET CORP | $37,772,059 | 7,869,179 | 5.25% | Shares |
| Rubric Capital Management LP | $36,158,098 | 7,532,937 | 5.03% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $33,651,259 | 7,010,679 | 4.68% | Shares |
| BARCLAYS PLC | $20,197,987 | 4,207,914 | 2.81% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $19,769,043 | 4,117,691 | 2.75% | Shares |
| GOLDMAN SACHS GROUP INC | $16,832,650 | 3,506,802 | 2.34% | Shares |
| BANK OF AMERICA CORP /DE/ | $12,701,745 | 2,646,197 | 1.77% | Shares |
| BlackBarn Capital Partners LP | $12,000,000 | 2,500,000 | 1.67% | Shares |
| Legal & General Group Plc | $11,837,409 | 2,466,127 | 1.65% | Shares |
| Woodline Partners LP | $10,952,909 | 2,281,856 | 1.52% | Shares |
| Jefferies Financial Group Inc. | $8,216,026 | 1,711,672 | 1.14% | Shares |
| NOMURA HOLDINGS INC | $7,857,989 | 1,637,081 | 1.09% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7,398,998 | 1,541,458 | 1.03% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $6,869,846 | 1,431,218 | 0.95% | Shares |
| NORTHERN TRUST CORP | $6,811,315 | 1,419,024 | 0.95% | Shares |
| OSAIC HOLDINGS, INC. | $6,469,756 | 1,347,866 | 0.90% | Shares |
| ADAR1 Capital Management, LLC | $6,087,106 | 1,268,147 | 0.85% | Shares |
| Deltroit Asset Management (UK) LLP | $5,760,000 | 1,200,000 | 0.80% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $5,449,738 | 1,135,362 | 0.76% | Shares |
| CITIGROUP INC | $4,220,338 | 879,237 | 0.59% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $3,771,945 | 838,210 | 0.52% | Shares |
| BANK OF MONTREAL /CAN/ | $3,734,102 | 777,938 | 0.52% | Shares |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $3,123,360 | 650,700 | 0.43% | Shares |
| MACKENZIE FINANCIAL CORP | $2,946,269 | 613,806 | 0.41% | Shares |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $2,889,638 | 602,008 | 0.40% | Shares |
| Western Standard LLC | $2,605,378 | 542,787 | 0.36% | Shares |
| Rangeley Capital, LLC | $2,400,000 | 500,000 | 0.33% | Shares |
| Nuveen, LLC | $2,383,723 | 496,609 | 0.33% | Shares |
| Man Group plc | $2,272,642 | 473,467 | 0.32% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $2,215,900 | 461,646 | 0.31% | Shares |
| Bank of New York Mellon Corp | $2,179,752 | 454,115 | 0.30% | Shares |
| CenterBook Partners LP | $2,136,725 | 445,151 | 0.30% | Shares |
| Freestone Capital Holdings, LLC | $2,124,000 | 442,500 | 0.30% | Shares |
| CITADEL ADVISORS LLC | $1,942,541 | 404,696 | 0.27% | Shares |
| KENNEDY CAPITAL MANAGEMENT LLC | $1,849,430 | 385,298 | 0.26% | Shares |
| D. E. Shaw & Co., Inc. | $1,832,942 | 381,863 | 0.25% | Shares |
| Swiss National Bank | $1,375,200 | 286,500 | 0.19% | Shares |
| Ledgewood Wealth Advisors, LLC | $1,336,493 | 278,436 | 0.19% | Shares |
| FMR LLC | $1,282,503 | 267,188 | 0.18% | Shares |
| Susquehanna Portfolio Strategies, LLC | $1,265,688 | 263,685 | 0.18% | Shares |
| Carrera Capital Advisors | $1,234,402 | 257,167 | 0.17% | Shares |
| Quinn Opportunity Partners LLC | $1,225,027 | 255,214 | 0.17% | Shares |
| Invesco Ltd. | $1,204,353 | 250,907 | 0.17% | Shares |
| UBS Group AG | $1,196,198 | 249,208 | 0.17% | Shares |
| STATE OF WISCONSIN INVESTMENT BOARD | $1,161,682 | 242,017 | 0.16% | Shares |
Activists & 5%+ owners 8 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Whitefort Capital Master Fund, LP, Whitefort Capital GP, LLC, Whitefort Capital Management, LP, Whitefort Capital Management GP, LLC, David Salanic, Joseph Kaplan ×5 filings | April 28, 2026 | 8.00% | Amendment | · | SEC |
| Roivant Sciences Ltd. ×14 filings | Feb. 25, 2025 | 20.50% | Amendment | · | SEC |
| Patrick Machado ×4 filings | July 17, 2019 | · | Initial filing | · | SEC |
| Dr. Andrew Lo ×5 filings | July 17, 2019 | · | Initial filing | · | SEC |
| SVF Investments (UK) Limited, SVF Holdings (UK) LLP, SoftBank Vision Fund L.P., SVF GP (Jersey) Limited ×4 filings | July 12, 2019 | · | Initial filing | · | SEC |
| QVT Financial LP, QVT Financial GP LLC, QVT Family Office Fund LP, QVT Associates GP LLC ×6 filings | July 12, 2019 | · | Initial filing | · | SEC |
| Dexxon Holdings Ltd., Dexcel Pharma Technologies Ltd., Dan Oren ×6 filings | July 12, 2019 | · | Initial filing | · | SEC |
| Viking Global Investors LP, Viking Global Performance LLC, Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Global Equities Master Ltd., Viking Long Fund GP LLC, Viking Long Fund Master Ltd., Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott, Rose S. Shabet ×7 filings | July 12, 2019 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 35 insiders · 17 officers · 19 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Lindsay Androski | President and CEO | Sept. 18, 2026 M | 72,337 | 0 | 0 | $0 |
| Michael J. Mcelhaugh | Interim President & CEO | Feb. 14, 2025 A | 1,658,003 | 0 | 0 | $0 |
| William H. Collier | President and CEO | Feb. 1, 2023 A | 216,500 | 0 | 0 | $0 |
| Mark J. Murray | President and CEO | March 1, 2019 A | 341,396 | 0 | 0 | $0 |
| Tuan Nguyen | Chief Financial Officer | Sept. 18, 2026 M | 159,963 | 0 | 0 | $0 |
| David C Hastings | Chief Financial Officer | Feb. 14, 2025 A | 249,824 | 0 | 0 | $0 |
| Bruce Cousins | EVP & Chief Financial Officer | March 24, 2017 A | · | 0 | 0 | $0 |
| Karen Sims | Chief Medical Officer | Feb. 14, 2025 A | 155,494 | 0 | 0 | $0 |
| Christopher J. Naftzger | General Counsel and CCO | Feb. 14, 2025 A | 140,544 | 0 | 0 | $0 |
| Michael J. Sofia | Chief Scientific Officer | Feb. 1, 2024 A | 1,485,121 | 0 | 0 | $0 |
| Elizabeth Howard | EVP, GC, Compliance | Feb. 1, 2023 A | 86,024 | 0 | 0 | $0 |
| Gaston Picchio | Chief Development Officer | Jan. 20, 2022 A | · | 0 | 0 | $0 |
| Koert Vandenenden | Chief Accounting Officer | Dec. 11, 2018 A | · | 0 | 0 | $0 |
| William T. Symonds | Chief Development Officer | April 16, 2018 A | · | 0 | 0 | $0 |
| Peter Lutwyche | Chief Technology Officer | March 24, 2017 A | · | 0 | 0 | $0 |
| Michael J. Abrams | Managing Director | Aug. 16, 2016 M | 42,097 | 0 | 0 | $0 |
| Mark Kowalski | Sr VP & Chief Medical Officer | March 15, 2016 A | · | 0 | 0 | $0 |
| Roger Sawhney | Director | Sept. 18, 2026 M | 30,825 | 0 | 0 | $0 |
| Robert A Beardsley | Director | Sept. 18, 2026 M | 32,276 | 0 | 0 | $0 |
| Anuj Hasija | Director | March 18, 2025 A | · | 0 | 0 | $0 |
| Keith S Manchester | Director | Aug. 14, 2024 M | 46,069 | 0 | 0 | $0 |
| Melissa Rewolinski | Director | May 23, 2024 A | · | 0 | 0 | $0 |
| Frank Torti | Director | May 23, 2024 A | · | 0 | 0 | $0 |
| James R Meyers | Director | May 23, 2024 A | · | 0 | 0 | $0 |
| Daniel D Burgess | Director | May 23, 2024 A | · | 0 | 0 | $0 |
| Richard C Henriques JR | Director | May 23, 2024 A | 1,000 | 0 | 0 | $0 |
| Tram Tran | Director | May 25, 2022 A | · | 0 | 0 | $0 |
| Andrew Cheng | Director | June 3, 2021 A | · | 0 | 0 | $0 |
| Myrtle S Potter | Director | Aug. 17, 2019 A | · | 0 | 0 | $0 |
| Vivek Ramaswamy | Director | June 19, 2018 A | · | 0 | 0 | $0 |
| Herbert J Conrad | Director | June 19, 2018 A | · | 0 | 0 | $0 |
| Frank Karbe | Director | June 21, 2017 A | · | 0 | 0 | $0 |
| Roivant Sciences Ltd. | 10% owner | Oct. 18, 2021 C | 38,847,462 | 0 | 0 | $0 |
| Andrew Lo | 10% owner | Jan. 12, 2018 P | · | 0 | 0 | $0 |
| Patrick Machado | 10% owner | Jan. 12, 2018 P | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 26 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0.68% | 72,962 NS | July 31, 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0.62% | 521,191 NS | July 31, 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0.49% | 23,611 SH | Oct. 1, 2026 | Daily |
| IWC · iShares Trust | 0.19% | 545,721 SH | Sept. 11, 2026 | Daily |
| LABU · Direxion Shares ETF Trust | 0.11% | 124,896 NS | July 31, 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.06% | 14,124 SH | Oct. 1, 2026 | Daily |
| IBB · iShares Trust | 0.06% | 1,201,130 SH | Sept. 11, 2026 | Daily |
| IWO · iShares Trust | 0.05% | 1,506,889 SH | Sept. 11, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.05% | 172,487 SH | Aug. 19, 2026 | Daily |
| PWS · Pacer Funds Trust | 0.03% | 1,706 NS | July 31, 2026 | N-PORT |
| IWM · iShares Trust | 0.03% | 4,035,105 SH | Sept. 11, 2026 | Daily |
| RSSL · Global X Funds | 0.02% | 76,843 NS | July 31, 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.02% | 122,630 SH | Oct. 1, 2026 | Daily |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.02% | 925,044 SH | Aug. 19, 2026 | Daily |
| ISCG · iShares Trust | 0.01% | 24,707 SH | Sept. 11, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.01% | 1,810,587 SH | Aug. 19, 2026 | Daily |
| VHT · VANGUARD WORLD FUND | 0.01% | 430,244 SH | Aug. 19, 2026 | Daily |
| WSML · iShares Trust | 0.01% | 11,624 SH | Sept. 9, 2026 | Daily |
| FHLC · FIDELITY COVINGTON TRUST | 0.01% | 66,333 NS | July 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.00% | 265,986 SH | Sept. 11, 2026 | Daily |
| IWV · iShares Trust | 0.00% | 49,783 SH | Sept. 9, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 5,034,547 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 13,683 SH | Aug. 19, 2026 | Daily |
| ISCB · iShares Trust | · | 6,673 SH | Sept. 11, 2026 | Daily |
| ISCV · iShares Trust | · | 13,314 SH | Sept. 11, 2026 | Daily |
| SMMV · iShares Trust | · | 60,845 SH | Sept. 1, 2026 | Daily |
ABUS Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 7 analysts
BUY
Median target
$5.39
+21.0%
3 42.9%
Strong Buy
3 42.9%
Buy
1 14.3%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
1 analysts · 2026-09-28Mean target $5.39 +21.0%
Low$5.39
Mean$5.39
High$5.39
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 12, 2026